Aetram Research India: NIFTY PHARMA Weekly Sector Outlook
Nifty Pharma Extends Powerful Recovery Above 27,000; Holding 26,800 Supports Further Upside, While 26,300 Weakness Could Trigger Profit Booking - 31.10.2026
Current Market Price: 27124.85
Market Prediction:
- Nifty Pharma has accelerated sharply from recent lows and now trades well above its major moving averages. RSI near 71 signals strong momentum but also elevated conditions. ADX confirms strengthening trend intensity, while MACD remains firmly positive. Holding 26,800 favours 27,400–27,800, whereas 26,300 weakness may invite profit booking.
Upcoming Events:
- Sai Life Sciences quarterly results may strengthen sector confidence.
- Continued pharmaceutical earnings strength could sustain sector participation
- Unexpected regulatory setbacks could trigger selective pharma volatility
Major Support and Resistance:
- Support: 26800, 26300, 26000
- Resistance: 27400, 27800, 28200
Volume Analysis:
- Recent upside acceleration has been accompanied by visibly stronger participation, confirming fresh demand near higher levels. However, elevated momentum warrants caution. Healthy volume above 27,400 may extend strength, while distribution near highs could encourage profit booking.
Final Take Away:
- Nifty Pharma currently carries one of the stronger momentum structures, with price firmly above key averages and trend strength expanding. Holding 26,800 keeps buyers dominant, while 27,400 clearance may open further upside toward 27,800–28,200.
Next Week Prediction:
- Next week may favour continued Pharma strength while 26,800 holds, though elevated momentum could create volatility; acceptance above 27,400 may extend gains toward 27,800–28,200.
Scenario-Based Outlook:
- Bullish Scenario: Above 27400, price may move toward 27800–28200 zone
- Bearish Scenario: Below 26300, downside risk toward 26000–25600 zone
- Neutral Scenario: Between 26300–27400, consolidation likely
Disclaimer: This research report is for informational purposes only. This is not an offer to buy or sell securities. Past performance is not indicative of future results. There is no guarantee of returns. Investments in securities are subject to market risks including loss of capital. Investors should consult their financial advisor before making any investment decisions.
